Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's Disease.

PubWeight™: 1.05‹?› | Rank: Top 15%

🔗 View Article (PMID 15674913)

Published in Cochrane Database Syst Rev on January 25, 2005

Authors

A K Akobeng1, E Gardener

Author Affiliations

1: Department of Paediatric Gastroenterology, Central Manchester and Manchester Children's University Hospitals, Booth Hall Children's Hospital, Charlestown Road, Blackley, Manchester, UK, M9 7AA.

Articles citing this

European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut (2006) 3.59

Inflammatory Bowel Disease. Dtsch Arztebl Int (2016) 1.56

Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol (2008) 1.52

Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in Japan. J Gastroenterol (2012) 1.40

A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease. Dig Dis Sci (2008) 1.26

Vedolizumab for the treatment of ulcerative colitis and Crohn's disease. Immunotherapy (2012) 1.04

Medical management of Crohn's disease. BMJ (2008) 0.97

Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease. Therap Adv Gastroenterol (2011) 0.92

Pharmacogenetics in inflammatory bowel disease. World J Gastroenterol (2006) 0.90

Inflammatory bowel disease in children: current trends. J Gastroenterol (2010) 0.87

The role of enteral nutrition in patients with inflammatory bowel disease: current aspects. Biomed Res Int (2015) 0.85

Probiotics in inflammatory bowel diseases and associated conditions. Nutrients (2011) 0.85

Second Korean guidelines for the management of Crohn's disease. Intest Res (2017) 0.82

Conventional therapy for Crohn's disease. World J Gastroenterol (2006) 0.82

Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete? World J Gastroenterol (2006) 0.82

Management of Crohn's disease - are guidelines transferred to clinical practice? United European Gastroenterol J (2015) 0.81

Optimal Endpoint of Therapy in IBD: An Update on Factors Determining a Successful Drug Withdrawal. Gastroenterol Res Pract (2015) 0.79

Evaluation of anti-inflammatory effect of anti-platelet agent-clopidogrel in experimentally induced inflammatory bowel disease. Indian J Pharmacol (2012) 0.76

Searching for the delta: 5-aminosalicylic Acid therapy for Crohn's disease. Gastroenterol Hepatol (N Y) (2011) 0.75

Current Controversies in Crohn's Disease: A Roundtable Discussion of the BRIDGe Group. Gastroenterol Hepatol (N Y) (2008) 0.75

Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn's disease. Clin Exp Gastroenterol (2009) 0.75

Management of inflammatory bowel diseases in Eastern Europe. Postgrad Med J (2006) 0.75

Vedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel disease. J Nat Sci Biol Med (2016) 0.75

Crohn's disease: a clinical update. Therap Adv Gastroenterol (2015) 0.75